Publication,

KWM issues Doing Business in China(2020)

Current site :    CN   |   EN
Australia
Belgium
China
China Hong Kong SAR
Germany
Italy
Japan
Singapore
Spain
UAE
United Kingdom
United States
Global

2019-2020 have been challenging years for both China and the world. China has had to contend with both the fallout from the COVID-2019 pandemic as well as the trade conflict between China and the US.

China's response has largely been to think BIG. Regulatory reform, rebalancing a transition to an innovative economy and embracing globalization. In addition China has shown it can still think BIG domestically with the Greater Bay Area initiative. In China the only constant is change!

In this publication, we explore the key questions being asked by clients looking to unlock investment opportunities in China such as: What are the best opportunities for investing in China? What are the challenges? How do other investors deal with the key issues? How do I deal with regulatory change?

We hope that this publication will demystify the China challenges but also the China opportunities and we can add value to your business in China and would be delighted to discuss opportunities with you further.

DOWNLOAD PUBLICATION
Doing Business in China
This publication covers the overall investment environment and industrial overview of the Chinese market, guiding foreign enterprises investing in China.

Download

32.4MB, 42 Pages

LATEST THINKING
Insight
New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting.

19 May 2022

Publication
Since 2017, KWM has issued the Series, Think Tank Report: Law and Practice under the Belt and Road Initiative. As the fifth instalment of the Series, this pamphlet comprises two parts: “Overview” and “Introduction by Countries”. Authored by KWM lawyers focusing on investment, financing, construction and projects, M&A, trade, compliance, and dispute resolution, this pamphlet will present you our experience and insights from different perspectives.

14 May 2022

Insight
Under the Chinese medical device regulatory regime, as filing/registration is compulsory prior to marketization, the legality of use of unregistered in vitro diagnostics reagents (“IVD”) in laboratory-developed testing (“LDT”) has been in a grey area for a long time.

10 May 2022